

HENNER DENNIS  
Form 4  
January 12, 2015

**FORM 4**

**UNITED STATES SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549**

OMB APPROVAL

OMB Number: 3235-0287  
Expires: January 31, 2015  
Estimated average burden hours per response... 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

1. Name and Address of Reporting Person \*  
Clarus Lifesciences II, L.P.

2. Issuer Name and Ticker or Trading Symbol  
AERIE PHARMACEUTICALS INC  
[AERI]

5. Relationship of Reporting Person(s) to Issuer

(Check all applicable)

(Last) (First) (Middle)

3. Date of Earliest Transaction  
(Month/Day/Year)  
01/08/2015

\_\_\_\_ Director  
\_\_\_\_ Officer (give title below)  
\_\_\_\_ 10% Owner  
\_\_\_\_ Other (specify below)

C/O CLARUS VENTURES,  
LLC, 101 MAIN STREET, SUITE  
1210

(Street)

4. If Amendment, Date Original Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check Applicable Line)  
\_\_\_\_ Form filed by One Reporting Person  
\_X\_ Form filed by More than One Reporting Person

CAMBRIDGE, MA 02142

(City) (State) (Zip)

**Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned**

| 1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Ownership (Instr. 4) |
|---------------------------------|--------------------------------------|--|--------------------------------|---|---|--|-----------------------------------|
|                                 |                                      |  | Code                           | V   | Amount  | (D)  | Price                             |
| Common Stock                    | 01/08/2015                           |  | S                              |   | 175,000   | D  | \$ 31.11                          |
|                                 |                                      |  |                                |   |   | (2)  | 3,324,259                         |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.**

SEC 1474  
(9-02)

Edgar Filing: HENNER DENNIS - Form 4

**Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned**  
(e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Underlying Securities (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of Derivative Securities Owned Following Transaction (Instr. 3 and 4) |
|--|--|--------------------------------------|--|--------------------------------|---|--|---|--|---|
|  |  |                                      |  | Code                           | V (A) (D)   | Date Exercisable   | Expiration Date   | Title                                      | Amount or Number of Shares  |

## Reporting Owners

| Reporting Owner Name / Address   | Relationships |           |         |       |
|--|---------------|-----------|---------|-------|
|  | Director      | 10% Owner | Officer | Other |
| Clarus Lifesciences II, L.P.<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142 |               | X         |         |       |
| Clarus Ventures II GP, L.P.<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142  |               | X         |         |       |
| Clarus Ventures II, LLC<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142      |               | X         |         |       |
| GALAKATOS NICHOLAS<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142           |               | X         |         |       |
| HENNER DENNIS<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                | X             | X         |         |       |
| LIPTAK ROBERT<br>C/O CLARUS VENTURES, LLC<br>101 MAIN STREET, SUITE 1210<br>CAMBRIDGE, MA 02142                |               | X         |         |       |

Simon Nicholas  
 C/O CLARUS VENTURES, LLC  
 101 MAIN STREET, SUITE 1210  
 CAMBRIDGE, MA 02142 X

STEINMETZ MICHAEL  
 C/O CLARUS VENTURES, LLC  
 101 MAIN STREET, SUITE 1210  
 CAMBRIDGE, MA 02142 X

WHEELER KURT  
 C/O CLARUS VENTURES, LLC  
 101 MAIN STREET, SUITE 1210  
 CAMBRIDGE, MA 02142 X

## Signatures

/s/ Robert Liptak, Manager of Clarus Ventures II, LLC, general partner of Clarus Ventures II GP, L.P., general partner of Clarus Lifesciences II, L.P. 01/12/2015  
 Date  
 \_\_Signature of Reporting Person

/s/ Robert Liptak, Manager of Clarus Ventures II, LLC, general partner of Clarus Venture II GP, L.P. 01/12/2015  
 Date  
 \_\_Signature of Reporting Person

/s/ Robert Liptak, Manager of Clarus Ventures II, LLC 01/12/2015  
 Date  
 \_\_Signature of Reporting Person

/s/ Robert Liptak, on behalf of Dennis Henner 01/12/2015  
 Date  
 \_\_Signature of Reporting Person

/s/ Robert Liptak, on behalf of Nicholas Galakatos 01/12/2015  
 Date  
 \_\_Signature of Reporting Person

/s/ Robert Liptak 01/12/2015  
 Date  
 \_\_Signature of Reporting Person

/s/ Robert Liptak, on behalf of Nicholas Simon 01/12/2015  
 Date  
 \_\_Signature of Reporting Person

/s/ Robert Liptak, on behalf of Michael Steinmetz 01/12/2015  
 Date  
 \_\_Signature of Reporting Person

/s/ Robert Liptak, on behalf of Kurt Wheeler 01/12/2015  
 Date  
 \_\_Signature of Reporting Person

## Explanation of Responses:

\* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) The price reflected is the weighted-average sale price for shares sold. The range of sale prices for the transactions reported was \$31.00 to \$31.25 per shares. The reporting person undertakes to provide, upon request by the SEC staff, the issuer, or a security holder of the issuer, full information regarding the number of shares sold at each separate price.

(2) Securities held of record by Clarus Lifesciences II, L.P. ("Clarus"). Clarus Ventures II GP, L.P. (the "GPLP"), as the sole general partner of Clarus, may be deemed to beneficially own certain of the shares held of record by Clarus. The GPLP disclaims beneficial ownership of all shares held of record by Clarus in which the GPLP does not have an actual pecuniary interest. Clarus Ventures II, LLC (the "GPLLC"), as the sole general partner of the GPLP, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler, as individual Managing Directors of the GPLLC, may be deemed to beneficially own certain of the shares held of record by Clarus. Each of the GPLLC and Messrs. Galakatos, Henner, Liptak, Simon, Steinmetz and Wheeler disclaims beneficial ownership of all shares held of record by Clarus in which it or he, as applicable, does not have an actual pecuniary interest.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.